Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 3 von 5

Details

Autor(en) / Beteiligte
Titel
Novel Biocompatible Amino Acids-Functionalized Three-dimensional Graphene Foams: As the Attractive and Promising Cisplatin Carriers for Sustained Release Goals
Ist Teil von
  • International journal of pharmaceutics, 2020-11, Vol.589, p.119857, Article 119857
Ort / Verlag
Netherlands: Elsevier B.V
Erscheinungsjahr
2020
Quelle
Alma/SFX Local Collection
Beschreibungen/Notizen
  • [Display omitted] •Novel 3D amino acids-functionalized GO foams were prepared.•GO foams functionalized by Alanine, Cysteine and Glycine amino acids.•Prepared foams had good biocompatibility and bioactivity.•Amino acids-functionalized GO foams exhibited a sustained drug release behavior. Application of amino acids-immobilized porous materials for drug delivery studies has been attracted a lot of attention in the recent years. In this study, amino acids-grafted graphene foams were prepared by anchoring of Alanine (Ala), Cysteine (Cys) and Glycine (Gly) amino acids on the surface of graphene oxide (GO) nanostructures and used as the novel biocompatible carriers to control releasing of the cisplatin as the cytotoxic anticancer drug. The characterization of prepared compounds was done by the FT-IR, Raman, TGA, N2 adsorption–desorption isotherms, SEM, and TEM techniques. Adsorption and in vitro release behavior of amino acids-functionalized foams were studied using ICP standard method. The results show that the drug loading amount and the drug releasing rate are significantly enhanced upon functionalization process. The Ala-Foam sample with the larger surface area and pore volume showed a higher loading content (4.53%) than other samples. In addition, the MTT test on the two MCF-7 and HepG2 human cancer cell lines exhibited an acceptable biocompatibility and sustainable drug releasing from the carriers up to 48 h, leading to the dosage frequency decrease and the patient compliance improvement.
Sprache
Englisch
Identifikatoren
ISSN: 0378-5173
eISSN: 1873-3476
DOI: 10.1016/j.ijpharm.2020.119857
Titel-ID: cdi_crossref_primary_10_1016_j_ijpharm_2020_119857

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX